Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Lerochol Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.768

    Lerodalcibep-liga (Lerochol)

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.768 alerts

    Get alerted when Policy CP.PHAR.768 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Lerochol, a PCSK9 inhibitor used with diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It applies to QualChoice commercial, HIM/ICHRA, and Medicaid members.

    Policy Summary
    PayerQualChoice
    PolicyLerodalcibep-liga (Lerochol)
    Policy CodePolicy CP.PHAR.768
    Change TypeModified
    Effective DateMar 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit a recent LDL-C result obtained within the last 60 days and the proposed Lerochol dose and treatment plan.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added the ICHRA line of business.

    For all indications, the moderate- or low-intensity statin requirement was changed from prior use of one high-intensity statin with LDL remaining at least 70 mg/dL to failure to achieve the LDL goal applicable to the specific indication.

    The recent LDL requirement for members with a history of ASCVD was changed to at least 55 mg/dL regardless of very-high-risk status.

    Examples of increased cardiovascular-event risk were expanded to include diabetes, a 10-year estimated ASCVD risk of at least 10%, and a CAC score of 100 to 299 AU.

    For heterozygous familial hypercholesterolemia, baseline LDL was simplified to at least 160 mg/dL for all ages and the recent LDL requirement was revised to at least 70 mg/dL.

    For severe primary hypercholesterolemia with ASCVD risk factors, a recent LDL requirement of at least 70 mg/dL was added, while the at-least-100-mg/dL requirement was clarified as applying to patients without ASCVD risk factors.

    AdultsMinimum age for initial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    300 mg/month
    Maximum Lerochol dose
    ≥55 mg/dLRecent LDL-C threshold with ASCVD
    ≥70 mg/dLRecent LDL-C threshold for HeFH or increased risk
    12 months Medicaid/HIM/ICHRA; 6 months commercialApproval duration
    300 mg SC monthlyLerochol dosing regimen

    Coverage Criteria

    Initial Therapy Criteria

    Covered when all applicable requirements are met:

    Initial approval

    • Qualifying diagnosis and cardiovascular risk

      • HeFH with baseline LDL-C ≥160 mg/dL before any lipid-lowering pharmacologic therapy, confirmed by either a WHO/Dutch Lipid Network score >8 or a definite Simon Broome diagnosis.Baseline LDL-C ≥160 mg/dL; WHO/Dutch score >8

        See Appendix D.

      • Primary hypercholesterolemia not HeFH: Baseline LDL-C was ≥190 mg/dL before any lipid-lowering pharmacologic therapy, with either confirmatory genetic testing for a genetically mediated form or documentation that secondary hypercholesterolemia causes have been ruled out.Baseline LDL-C ≥190 mg/dL

        Potential secondary causes include poor diet, hypothyroidism, obstructive liver disease, renal liver disease, nephrosis, and contributory medications.

      • Increased cardiovascular-event risk: At least one of the following is present: diabetes; 10-year estimated ASCVD risk ≥10%; CAC score 100–299 Agatston units; or history of ASCVD.ASCVD risk ≥10%; CAC 100–299 AU

        ASCVD history includes acute coronary syndromes, clinically significant CHD, CAC ≥300 AU, revascularization, myocardial infarction, peripheral arterial disease of presumed atherosclerotic origin, stable or unstable angina, or stroke/TIA.

    • Prescriber and age: Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist, and member is age ≥18 years.Age ≥18 years
    • Preferred PCSK9 inhibitor trial: Failure of an 8-week trial of a preferred PCSK9 inhibitor at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred.8 weeks

      Prior authorization may be required for PCSK9 inhibitors.

    • Statin pathway: For members on statin therapy, Lerochol is prescribed with a maximally tolerated statin and the member has adhered for at least 8 weeks to a high-intensity statin, or to a moderate/low-intensity statin plus either prior high-intensity statin failure or skeletal-muscle symptoms with both rosuvastatin and atorvastatin. For members not on statin therapy, statin therapy is contraindicated or the member has tried at least two statins, including one hydrophilic statin, and meets the specified risk-factor or SAMS criteria.At least 8 weeks of statin adherence; at least 2 statins for intolerance

      SAMS documentation must show persistence for at least 2 weeks, resolution after discontinuation, recurrence on rechallenge, and rechallenge using lowest-dose titration and/or intermittent dosing when applicable.

    • Ezetimibe therapy: Member has been adherent for at least 4 months to ezetimibe used with a maximally tolerated statin, unless ezetimibe is contraindicated or there is a history of ezetimibe intolerance.4 months
    • LDL-C and regimen limits: Recent LDL-C meets the threshold for the member's ASCVD or hypercholesterolemia risk category; treatment does not include Leqvio, Juxtapid, Repatha, or Praluent; and the dose does not exceed 300 mg per month.LDL-C ≥55, ≥70, or ≥100 mg/dL within 60 days; dose ≤300 mg/month

    Other Diagnoses and Indications

    Other diagnoses and indications must be handled under the applicable line-of-business policy:

    Other diagnosis or indication: If the drug has undergone a label change within the last 6 months that is not reflected in this policy, refer to the applicable no-coverage or non-formulary policy based on formulary or PDL status and line of business. If the requested use is not specifically listed under diagnoses for which coverage is not authorized and the label-change pathway does not apply, refer to the applicable off-label use policy.Label change within 6 months

    Use the applicable commercial, HIM/ICHRA, or Medicaid policy.

    Continuation Therapy Criteria

    Continued coverage requires all applicable criteria to be met:

    Continuation therapy: Member is currently receiving Lerochol through the Centene benefit or previously met initial approval criteria, or is receiving it under applicable state and product continuity-of-care regulations; statin-tolerant members remain adherent to a maximally tolerated statin; laboratory results within the last 3 months show LDL-C reduction since Lerochol initiation; treatment does not include Leqvio, Juxtapid, Repatha, or Praluent; and any dose increase does not exceed 300 mg per month.LDL-C reduction within 3 months; dose ≤300 mg/month

    See state-specific continuity-of-care addendums CC.PHARM.03A and CC.PHARM.03B. Illinois HIM step-therapy requirements do not apply under IL HB 5395.

    Dutch Lipid Clinic Network HeFH Diagnosis Criteria

    Definite familial hypercholesterolemia requires a total score greater than 8 points. Select the highest applicable score from each category and add the category scores:

    Definite HeFH

    • Family history: First-degree relative with premature coronary or vascular disease; first-degree relative with LDL-C above the 95th percentile; first-degree relative with tendinous xanthomata or arcus cornealis; or child under 18 years with LDL-C above the 95th percentile.

      Use the highest applicable family-history score.

    • Clinical history: Premature coronary artery disease or premature cerebral or peripheral vascular disease.

      Use the highest applicable clinical-history score.

    • Physical examination: Tendinous xanthomata or arcus cornealis before age 45 years.6 points for tendinous xanthomata; 4 points for arcus cornealis

    Simon Broome Definite FH Diagnosis Criteria

    Definite familial hypercholesterolemia requires both a qualifying cholesterol or LDL-C level and a qualifying tendon or genetic finding:

    Definite FH

    • Cholesterol criterion: Adult total cholesterol >7.5 mmol/L (290 mg/dL); child under 16 years total cholesterol >6.7 mmol/L (260 mg/dL); adult LDL-C >4.9 mmol/L (190 mg/dL); or child LDL-C >4.0 mmol/L.

      Use pretreatment or highest-on-treatment LDL-C when applicable.

    • Tendon or DNA criterion: Tendinous xanthomas in the patient or a qualifying relative, or DNA-based evidence of an LDL receptor mutation or familial defective apo B100.One required

      Qualifying relatives include a parent, child, sibling, grandparent, aunt, or uncle.

    Coverage is excluded when the treatment plan coadministers Lerochol with Leqvio, Juxtapid, Repatha, or Praluent. This restriction applies to both initial and continued therapy, and the Lerochol dose must not exceed 300 mg per month.

    Non-FDA-approved indications that are not addressed by this policy are not authorized unless sufficient efficacy and safety documentation supports coverage under the applicable off-label use policy or evidence-of-coverage documents. Route requests according to the member’s line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.

    Statin therapy is precluded or limited when the member has decompensated liver disease, laboratory-confirmed acute liver injury or rhabdomyolysis resulting from statin treatment, or immune-mediated hypersensitivity to the statin class demonstrated by an allergic reaction to at least two different statins. Ezetimibe is precluded in moderate or severe hepatic impairment (Child-Pugh class B or C) or with ezetimibe hypersensitivity.

    Coding and Clinical Thresholds

    HCPCS CodesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    HeFH baseline LDL-C
    Threshold≥160 mg/dL
    Applies toHeFH
    Measurement timingBefore any lipid-lowering pharmacologic therapy
    Non-HeFH primary hypercholesterolemia baseline LDL-C
    Threshold≥190 mg/dL
    Applies toPrimary hypercholesterolemia that is not HeFH
    Measurement timingBefore any lipid-lowering pharmacologic therapy

    Provider Actions and Authorization Requirements

    Documentation Required

    Submit Supporting Clinical Records

    Submit documentation supporting that the member meets all applicable approval criteria, including office chart notes, laboratory results, and other relevant clinical information.

    • Clinical records must support the requested diagnosis, risk status, prior treatment, contraindications or intolerance, laboratory findings, and treatment plan.
    Billing Rule

    Route Other Indications to the Applicable Policy

    Route requests for other indications or uses to the applicable line-of-business policy. Follow the formulary, PDL, non-formulary, or off-label pathway as appropriate.

    • Recently changed indication, age, or dosing regimen: use the applicable no-coverage-criteria policy for formulary or PDL drugs, or the applicable non-formulary policy for drugs not on the formulary or PDL.

    Background

    Lerodalcibep-liga (Lerochol) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor used as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The policy focuses on severe or genetically mediated hypercholesterolemia and elevated cardiovascular-event risk after appropriate lipid-lowering therapy.

    Definitions

    ASCVD
    AbbreviationASCVD
    Full termAtherosclerotic cardiovascular disease
    Policy useASCVD history is used to determine the applicable recent LDL-C threshold
    HeFH
    AbbreviationHeFH
    Full termHeterozygous familial hypercholesterolemia
    Policy useHeFH is a qualifying hypercholesterolemia diagnosis under the policy

    Initial Therapy Criteria

    Initial Approval Criteria

    Initial therapy is covered when all applicable requirements are met:

    Initial approval

    • Qualifying diagnosis and cardiovascular risk

      • HeFH with baseline LDL-C ≥160 mg/dL before any lipid-lowering pharmacologic therapy, confirmed by either a WHO/Dutch Lipid Network score >8 or a definite Simon Broome diagnosis.Baseline LDL-C ≥160 mg/dL; WHO/Dutch score >8
      • Primary hypercholesterolemia not HeFH: Baseline LDL-C was ≥190 mg/dL before any lipid-lowering pharmacologic therapy, with either confirmatory genetic testing for a genetically mediated form or documentation that secondary hypercholesterolemia causes have been ruled out.Baseline LDL-C ≥190 mg/dL

    Continuation Criteria

    Continuation Approval Criteria

    Continued therapy is covered when all criteria are met:

    Continuation approval: Member meets benefit or prior-approval/continuity-of-care eligibility; statin-tolerant members document adherence to maximally tolerated statin therapy; laboratory results within the last 3 months show LDL-C reduction after Lerochol initiation; no prohibited coadministration with Leqvio, Juxtapid, Repatha, or Praluent is planned; and any dose increase is no more than 300 mg per month.LDL-C reduction within 3 months; dose ≤300 mg/month

    See state-specific continuity-of-care addendums CC.PHARM.03A and CC.PHARM.03B. Illinois HIM step-therapy requirements do not apply under IL HB 5395.

    Step Therapy

    StepRequirementDetails
    1Trial of a preferred PCSK9 inhibitorThe member must fail an 8-week trial at up to maximally indicated doses, unless the drug is contraindicated or clinically significant adverse effects occur.
    StepRequirementDetails
    2Use maximally tolerated statin therapy or satisfy the documented contraindication/intolerance pathwayWhen taking a statin, use Lerochol with the maximally tolerated dose and document at least 8 weeks of adherence to a high-intensity statin, or to a moderate- or low-intensity statin with prior high-intensity statin failure or skeletal-muscle symptoms with both rosuvastatin and atorvastatin. If not taking a statin, document a contraindication or qualifying intolerance pathway, including trials of at least two statins with one hydrophilic statin when applicable.
    StepRequirementDetails
    3Adherence to ezetimibe used with a maximally tolerated statinDocument adherence for at least 4 months, unless ezetimibe is contraindicated or there is a documented history of ezetimibe intolerance.
    StepRequirementDetails
    ContinuationContinue concomitant statin therapy when toleratedPatients should remain on concomitant statin therapy when tolerated because of established long-term cardiovascular benefits.

    Quantity Limits

    Lerochol quantity limit
    Quantity limit300 mg
    FrequencyPer month
    Applies toLerochol
    Lerodalcibep-liga (Lerochol) quantity limit
    ProductLerodalcibep-liga (Lerochol)
    Maximum dose300 mg per month
    Usual regimen300 mg subcutaneously monthly
    Policy Summary
    PayerQualChoice
    PolicyLerodalcibep-liga (Lerochol)
    Policy CodePolicy CP.PHAR.768
    Change TypeModified
    Effective DateMar 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit a recent LDL-C result obtained within the last 60 days and the proposed Lerochol dose and treatment plan.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Authorization RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep TherapyQuantity Limits

    Use the highest applicable physical-examination score.

  1. Cholesterol levels: LDL-C 155–189 mg/dL (4.0–4.9 mmol/L), 190–249 mg/dL (5.0–6.4 mmol/L), 250–329 mg/dL (6.5–8.4 mmol/L), or ≥330 mg/dL (≥8.5 mmol/L).1, 3, 5, or 8 points

    Use the highest applicable cholesterol score.

  2. DNA analysis: Functional mutation in the LDLR, apo B, or PCSK9 gene.8 points

    Add the DNA score to the other category scores.

  3. WHO/Dutch Lipid Network HeFH score
    Threshold>8
    Diagnostic toolWorld Health Organization/Dutch Lipid Network familial hypercholesterolemia diagnostic criteria
    UseConfirms HeFH diagnosis when the score is greater than 8
    ASCVD 10-year risk
    Threshold≥10%
    Measure10-year estimated ASCVD risk
    Risk categoryIncreased risk for cardiovascular events
    CAC score for increased cardiovascular-event risk
    Threshold≥100 to 299 Agatston units
    MeasureCoronary artery calcium score
    PurposeEvidence of increased risk for cardiovascular events
    CAC score qualifying as ASCVD history
    Threshold≥300 Agatston units
    MeasureCoronary artery calcium score
    ClassificationIncluded as a history of ASCVD
    Recent LDL-C with ASCVD history
    Threshold≥55 mg/dL
    Applies toMembers with a history of ASCVD
    Result timingWithin the last 60 days
    Recent LDL-C for HeFH or increased risk without ASCVD history
    Threshold≥70 mg/dL
    Applies toHeFH; severe primary hypercholesterolemia with ASCVD risk factors; or increased cardiovascular-event risk without a history of ASCVD
    Result timingWithin the last 60 days
    Recent LDL-C for severe primary hypercholesterolemia without ASCVD risk factors
    Threshold≥100 mg/dL
    Applies toSevere primary hypercholesterolemia without ASCVD risk factors
    Result timingWithin the last 60 days
    Lerochol dose limit
    Maximum dose≤300 mg per month
    DrugLerochol
    Continuation ruleAny dose increase must remain no more than 300 mg per month
    Dutch Lipid Clinic Network definite FH score
    Threshold>8 points
    Diagnostic methodSelect the highest score from each of five categories and add the scores together
    CategoriesFamily history, clinical history, physical examination, cholesterol levels, and DNA analysis
    LDL-C diagnostic thresholds in Dutch Lipid Clinic Network criteria
    LDL-C ≥330 mg/dL≥8.5 mmol/L
    LDL-C 250–329 mg/dL6.5–8.4 mmol/L
    LDL-C 190–249 mg/dL5.0–6.4 mmol/L
    LDL-C 155–189 mg/dL4.0–4.9 mmol/L
    Simon Broome adult cholesterol threshold
    Adult total cholesterol>290 mg/dL (7.5 mmol/L)
    Adult LDL-C>190 mg/dL (4.9 mmol/L)
    Additional requirementOne qualifying clinical or genetic criterion is also required for definite FH
    Simon Broome pediatric cholesterol threshold
    Children under 16: total cholesterol>260 mg/dL (6.7 mmol/L)
    Children: LDL-C>4.0 mmol/L
    Additional requirementOne qualifying clinical or genetic criterion is also required for definite FH
    ASCVD risk-factor lipid thresholds
    Lipoprotein(a) [Lp(a)]≥125 nmol/L or ≥50 mg/dL
    High-sensitivity C-reactive protein (hsCRP)≥2 mg/L on more than one occasion, if measured
    TriglyceridesPersistently ≥175 mg/dL (2 mmol/L) if nonfasting or ≥150 mg/dL (1.7 mmol/L) if fasting
    Other lipid thresholdsLDL-C persistently ≥160–189 mg/dL, non-HDL-C ≥190–219 mg/dL, or apoB ≥120 mg/dL
  4. Uses not specifically listed as noncovered and not addressed by a recent label-change pathway: use the applicable off-label policy.
  5. Commercial: CP.CPA.190 or CP.CPA.09; HIM/ICHRA: HIM.PA.33, HIM.PA.103, or HIM.PA.154; Medicaid: CP.PMN.255, CP.PMN.16, or CP.PMN.53.
  6. Prior Authorization

    Pharmacy Prior Authorization Required

    Lerochol requires prior authorization through the pharmacy utilization-management program before coverage can be approved.

    • Apply the initial or continued-therapy criteria, as applicable.
    • Approval duration is generally 12 months for Medicaid/HIM/ICHRA and 6 months or the member’s renewal date, whichever is longer, for commercial coverage.
    Step Therapy

    Preferred PCSK9 Inhibitor Trial

    Document failure of an 8-week trial of a preferred PCSK9 inhibitor at up to maximally indicated doses, unless the preferred agent is contraindicated or clinically significant adverse effects occurred.

    • Prior authorization may be required for preferred PCSK9 inhibitors.
    • For Illinois HIM requests, this step-therapy requirement does not apply under IL HB 5395.
    Step Therapy

    Optimize Statin Therapy or Document Intolerance

    For members receiving statin therapy, prescribe Lerochol with a statin at the maximally tolerated dose and document adherence for at least the preceding 8 weeks.

    • Use a high-intensity statin, or a moderate- or low-intensity statin when the member previously used high-intensity atorvastatin at least 40 mg daily or rosuvastatin at least 20 mg daily for at least 8 continuous weeks without reaching the LDL-C goal.
    • The moderate- or low-intensity pathway may also be met when the member tried both rosuvastatin and atorvastatin and had skeletal-muscle symptoms with both that resolved after discontinuation.
    • For members not taking a statin, document a qualifying contraindication or intolerance pathway.
    • For Illinois HIM requests, these step-therapy requirements do not apply under IL HB 5395.
    Step Therapy

    Ezetimibe Trial Required

    Document adherence to ezetimibe used concomitantly with a statin at the maximally tolerated dose for at least the preceding 4 months, unless an applicable exception is documented.

    • The requirement is waived for ezetimibe contraindication or documented intolerance, such as associated diarrhea or upper respiratory tract infection.
    • For Illinois HIM requests, the step-therapy requirement does not apply under IL HB 5395.
    Note

    Continue Statin When Tolerated

    When tolerated, continue concomitant statin therapy because of its established long-term cardiovascular benefits.

    • Document the maximally tolerated statin dose and adherence for continuation requests when the member is statin tolerant.

    Unsupported block type: documentation

    Documentation Required

    Support All Approval Criteria

    Provide general clinical documentation demonstrating that every applicable approval criterion has been met.

    • Documentation should be internally consistent and identify the requested indication, prescriber or consultant, member age, diagnosis, risk findings, treatment history, laboratory results, dose, and planned concomitant therapy.
    Documentation Required

    Document Diagnosis and Cardiovascular Risk

    Document the qualifying diagnosis and cardiovascular risk profile, including baseline LDL-C measured before lipid-lowering pharmacologic therapy.

    • HeFH requires baseline LDL-C of at least 160 mg/dL and confirmation by a Dutch Lipid Clinic Network score greater than 8 or definite Simon Broome criteria.
    • Primary hypercholesterolemia that is not HeFH requires baseline LDL-C of at least 190 mg/dL plus genetic confirmation or documentation that secondary causes have been ruled out.
    • Alternatively, document increased cardiovascular-event risk through diabetes, 10-year ASCVD risk of at least 10%, CAC score of at least 100 AU, or qualifying ASCVD history.
    • Document that the prescriber is or consulted with a cardiologist, endocrinologist, or lipid specialist, and that the member is at least 18 years old.
    Documentation Required

    Document Prior Therapy and Intolerance

    Document all prior lipid-lowering therapy and the member’s response, adherence, tolerance, contraindications, or clinically significant adverse effects.

    • Include the preferred PCSK9 inhibitor trial or qualifying exception, statin regimen and adherence, prior high-intensity statin use when applicable, and ezetimibe adherence or exception.
    • For statin intolerance, document trials of at least two statins, including one hydrophilic statin such as pravastatin, fluvastatin, or rosuvastatin, and the applicable risk factors or SAMS rechallenge findings.
    • For Illinois HIM requests, identify when step therapy is not applied under IL HB 5395.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Documentation Required

    Document Treatment, Risk Factors, and Concomitant Therapy

    Document the complete lipid-lowering treatment history, tolerance, contraindications, risk factors, and intended concomitant statin plan.

    • Include prior statin and ezetimibe use, adherence, dose optimization, intolerance or contraindication evidence, and any preferred-PCSK9 inhibitor trial.
    • Document statin risk factors such as serious comorbidities, impaired renal or hepatic function, ALT elevations greater than 3 times the upper limit of normal or active liver disease, interacting medications, age over 75 years, hemorrhagic stroke history, or Asian ancestry.
    • State that the member will remain on a maximally tolerated statin when tolerated.
    Denial Risk

    Initial Approval Denial Risks

    Initial requests may be denied when required diagnosis, risk, prescriber, age, or step-therapy criteria are not established.

    • Denial risks include absent qualifying primary hypercholesterolemia or HeFH, insufficient baseline LDL-C, missing HeFH confirmation, unruled-out secondary causes, or no qualifying cardiovascular risk finding.
    • Requests may be denied when the member is under 18 or the prescriber is not a cardiologist, endocrinologist, lipid specialist, or acting in consultation with one.
    • Denial may result from failure to complete the preferred-PCSK9 inhibitor, statin, or ezetimibe requirements without a documented contraindication, intolerance, or Illinois HIM exception.
    • Incomplete documentation of recent LDL-C, dose, or other initial criteria may also result in denial.
    Denial Risk

    Prohibited Combination or Excessive Dose

    Do not submit a treatment plan that combines Lerochol with prohibited lipid-lowering agents or exceeds the maximum dose.

    • Prohibited coadministration: Leqvio, Juxtapid, Repatha, or Praluent.
    • Maximum dose: 300 mg per month, including an increased dose requested during continuation therapy.
    Denial Risk

    Continuation Approval Denial Risks

    Continuation requests may be denied when ongoing benefit, prior approval, or continuation requirements are not demonstrated.

    • Document current receipt of Lerochol, prior satisfaction of initial criteria, or qualifying continuity-of-care status.
    • Provide an LDL-C reduction since treatment initiation using laboratory results from within the last 3 months.
    • Document statin adherence when tolerated and confirm that prohibited combinations and excessive dosing are absent.
    Denial Risk

    Unaddressed Non-FDA-Approved Indication

    Non-FDA-approved indications not addressed by this policy are not covered unless sufficient efficacy and safety documentation is submitted under the applicable off-label policy or evidence of coverage document.

    • For commercial requests, use CP.CPA.09; for HIM/ICHRA, use HIM.PA.154; for Medicaid, use CP.PMN.53.
    • An unaddressed indication without the required supporting evidence may be denied.
    LDL-C
    AbbreviationLDL-C
    Full termLow-density lipoprotein cholesterol
    Policy useBaseline and recent LDL-C values are used in coverage criteria
    SAMS
    AbbreviationSAMS
    Full termStatin-associated muscle symptoms
    Typical symptomsMuscle pain, aching, cramps, or weakness, usually bilateral and involving large muscle groups
    CAC
    AbbreviationCAC
    Full termCoronary artery calcium
    MeasurementMeasured in Agatston units (AU)
    Dutch Lipid Clinic Network criteria
    Scoring methodSelect the highest score from each of five categories and add the category scores
    CategoriesFamily history, clinical history, physical examination, cholesterol levels, and DNA analysis
    Definite FH threshold>8 points
    Simon Broome definite familial hypercholesterolemia
    Required elementsOne qualifying cholesterol or LDL level plus one clinical or genetic criterion
    Clinical criterionTendinous xanthomas in the patient or a qualifying relative
    Genetic criterionDNA-based evidence of an LDL receptor mutation or familial defective apo B100
    Statin-associated muscle symptoms
    Common symptomsBilateral muscle pain, aching, cramps, or weakness
    Typical distributionLarge muscle groups, including the thigh, buttock, back, and shoulder girdle
    Strongest supporting evidenceSymptoms reappear with statin rechallenge and disappear after statin cessation
    Increased cardiovascular-event risk: At least one of diabetes; 10-year estimated ASCVD risk ≥10%; CAC score 100–299 Agatston units; or history of ASCVD is present.ASCVD risk ≥10%; CAC 100–299 AU

    ASCVD history includes acute coronary syndromes, clinically significant CHD, CAC ≥300 AU, revascularization, myocardial infarction, peripheral arterial disease of presumed atherosclerotic origin, stable or unstable angina, or stroke/TIA.

  7. Prescriber and age: Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist, and member is age ≥18 years.Age ≥18 years
  8. Preferred PCSK9 inhibitor trial: Failure of an 8-week trial of a preferred PCSK9 inhibitor at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred.8 weeks
  9. Statin pathway: For members on statin therapy, Lerochol is prescribed with a maximally tolerated statin and the member has adhered for at least 8 weeks to a high-intensity statin, or to a moderate/low-intensity statin plus either prior high-intensity statin failure or skeletal-muscle symptoms with both rosuvastatin and atorvastatin. For members not on statin therapy, statin therapy is contraindicated or the member has tried at least two statins, including one hydrophilic statin, and meets the specified risk-factor or SAMS criteria.At least 8 weeks of statin adherence; at least 2 statins for intolerance

    SAMS documentation must show persistence for at least 2 weeks, resolution after discontinuation, recurrence on rechallenge, and rechallenge using lowest-dose titration and/or intermittent dosing when applicable.

  10. Ezetimibe therapy: Member has been adherent for at least 4 months to ezetimibe used with a maximally tolerated statin, unless ezetimibe is contraindicated or there is a history of ezetimibe intolerance.4 months
  11. LDL-C and regimen limits: Recent LDL-C meets the threshold for the member's ASCVD or hypercholesterolemia risk category; treatment does not include Leqvio, Juxtapid, Repatha, or Praluent; and the dose does not exceed 300 mg per month.LDL-C ≥55, ≥70, or ≥100 mg/dL within 60 days; dose ≤300 mg/month